Propensity to Hospitalize Patients From the ED in European Centers.
Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · Apr 3, 2024
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how likely patients are to be admitted to the hospital after visiting the emergency department (ED) in various European centers. The goal is to create a tool that helps predict which patients might need to stay in the hospital based on their specific health conditions. By comparing how many patients are actually admitted to the hospital from each ED with how many would be expected to be admitted if all EDs performed similarly, researchers hope to better understand and improve the care provided in these emergency settings.
To be eligible for this study, you need to be an adult who visited the emergency department between January 1, 2021, and December 31, 2023. There are no specific health conditions or other exclusions to worry about, meaning anyone who meets the age requirement can participate. If you join the trial, you will help researchers gather important information that could lead to better predictions about hospital admissions, ultimately benefiting future patients in emergency care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult
- • Arrived at emergency department between 1 January 2021 and 31 December 2023
- Exclusion Criteria:
- • None
About Mario Negri Institute For Pharmacological Research
The Mario Negri Institute for Pharmacological Research is a leading Italian biomedical research organization dedicated to advancing pharmacological science and improving public health. Established in 1963, the Institute focuses on innovative research methodologies, drug development, and clinical trials aimed at understanding and treating various diseases. With a multidisciplinary team of scientists and clinicians, the Institute collaborates with national and international partners to translate research findings into clinical applications, contributing significantly to the fields of pharmacology, epidemiology, and biostatistics. Committed to excellence in research and ethical standards, the Mario Negri Institute plays a vital role in shaping the future of medical science and enhancing therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Guido Bertolini, MD
Principal Investigator
Istituto Di Ricerche Farmacologiche Mario Negri
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported